Fundamental Analysis of EFFECTOR THERAPEUTICS INC(NASDAQ:EFTR) stock

Fundamental Rating

Overall EFTR gets a fundamental rating of 0 out of 10. We evaluated EFTR against 588 industry peers in the Biotechnology industry. EFTR may be in some trouble as it scores bad on both profitability and health. EFTR has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

EFTR had negative earnings in the past year.

In the past year EFTR has reported a negative cash flow from operations.

The reported net income has been mixed in the past 5 years: EFTR reported negative net income in multiple years.

EFTR had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

EFTR has a Return On Assets of -174.26%. This is amonst the worse of the industry: EFTR underperforms 88.40% of its industry peers.

		Industry Rank	Sector Rank
ROA	-174.26%
ROE	N/A
ROIC	N/A

ROA(3y)-74.35%

ROA(5y)-100.13%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

EFTR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EFTR does not have a ROIC to compare to the WACC, probably because it is not profitable.

EFTR has less shares outstanding than it did 1 year ago.

EFTR has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -17.85, we must say that EFTR is in the distress zone and has some risk of bankruptcy.

EFTR's Altman-Z score of -17.85 is on the low side compared to the rest of the industry. EFTR is outperformed by 86.35% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-17.85

ROIC/WACCN/A

WACC8.06%

2.3 Liquidity

A Current Ratio of 0.77 indicates that EFTR may have some problems paying its short term obligations.

EFTR has a Current ratio of 0.77. This is amonst the worse of the industry: EFTR underperforms 92.32% of its industry peers.

A Quick Ratio of 0.77 indicates that EFTR may have some problems paying its short term obligations.

EFTR has a Quick ratio of 0.77. This is amonst the worse of the industry: EFTR underperforms 91.81% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.77
Quick Ratio	0.77

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for EFTR have decreased strongly by -190.22% in the last year.

The Revenue for EFTR has decreased by -100.00% in the past year. This is quite bad

EPS 1Y (TTM)-190.22%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q37.82%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2Q-100%

3.2 Future

EFTR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.92% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y68.8%

EPS Next 2Y37.03%

EPS Next 3Y24.92%

EPS Next 5Y14.92%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EFTR. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EFTR. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as EFTR's earnings are expected to grow with 24.92% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y37.03%

EPS Next 3Y24.92%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

EFTR does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EFFECTOR THERAPEUTICS INC

NASDAQ:EFTR (4/26/2024, 7:00:02 PM)

Premarket: 1.89 0 (0%)

1.89

+0.08 (+4.42%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap6.97M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-174.26%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.77
Quick Ratio	0.77
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-190.22%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y68.8%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

EFFECTOR THERAPEUTICS INC (EFTR)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens